Positive Pre-Market Momentum for Quhuo, Lyra Therapeutics and Marinus Pharmaceuticals
- May 26th, 2023
- 89 views
Quhuo Limited (Nasdaq: QH) announced remarkable achievements in its homestay sector operated by Chengtu Home during the Labor Day holiday.
According to Quhuo, they recorded an impressive average daily occupancy rate of 95%, representing a significant year-on-year growth of 265% and surpassing RMB12 million in sales revenue. Quhuo's Chairman and CEO, Leslie Yu, expressed satisfaction with Chengtu's vacation rentals, highlighting their value in localized life services.
Moving forward, Chengtu plans to invest more in lean operational management and innovate its business models to adapt to the evolving tourism sector and meet diverse client demands.
In pre-market, $QH is experiencing a positive trend, with an increase of $0.60 (+35.71%), currently trading at $2.28.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) has entered into a securities purchase agreement for a private placement that is expected to generate gross proceeds of approximately $50.0 million, subject to customary closing conditions.
$LYRA is showing a positive trend in pre-market, with a rise of $0.47 (+19.34%), currently trading at $2.90.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the approval of ZTALMY (ganaxolone) oral suspension. This recommendation is for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged two to 17 years. ZTALMY may also be continued for patients 18 years and older.
CDD is a rare genetic disorder characterized by severe neuro-developmental impairment and early-onset, difficult-to-control seizures.
In pre-market, $MRNS is exhibiting a slight increment of $0.13 (+1.85%), currently trading at $7.16.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Jazz Pharma, Zymeworks: Promising Data on Zanidatamab in HER2-Amplified BTC; Positive View on Trade Desk, Kura Sushi and Surgery PartnersJune 03rd, 2023
Globus Maritime: Profits, Revenue Decline YoY; Analysts See Opportunity in Paychex, Fluence Energy, Quaker and MovellaJune 02nd, 2023
Chijet Motor Debuts on Nasdaq, Market Experts Bullish on Ambrx, FibroGen, Bowlero, REGENXBIO and KopinJune 02nd, 2023